HC Wainwright Forecasts Strong Price Appreciation for Delcath Systems (NASDAQ:DCTH) Stock

Delcath Systems (NASDAQ:DCTH) had its target price increased by equities research analysts at HC Wainwright from $22.00 to $24.00 in a research report issued on Friday,Benzinga reports. The firm presently has a “buy” rating on the stock. HC Wainwright’s price target suggests a potential upside of 81.54% from the company’s current price.

Separately, Craig Hallum raised their price target on shares of Delcath Systems from $18.00 to $21.00 and gave the company a “buy” rating in a report on Friday, January 17th. One research analyst has rated the stock with a hold rating and four have assigned a buy rating to the company. According to data from MarketBeat, Delcath Systems presently has a consensus rating of “Moderate Buy” and an average target price of $22.75.

Delcath Systems Stock Down 1.6 %

Shares of NASDAQ:DCTH opened at $13.22 on Friday. The company has a market capitalization of $422.70 million, a price-to-earnings ratio of -9.79 and a beta of 0.82. The firm has a 50 day moving average of $14.40 and a 200 day moving average of $11.63. Delcath Systems has a 52 week low of $3.70 and a 52 week high of $16.97.

Delcath Systems (NASDAQ:DCTH) last released its quarterly earnings results on Thursday, March 6th. The company reported ($0.11) EPS for the quarter, missing the consensus estimate of ($0.10) by ($0.01). Delcath Systems had a negative return on equity of 338.16% and a negative net margin of 150.70%. The company had revenue of $15.10 million during the quarter, compared to the consensus estimate of $14.96 million. During the same period in the previous year, the firm posted ($0.48) earnings per share. On average, sell-side analysts expect that Delcath Systems will post -0.79 EPS for the current year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. Quarry LP acquired a new stake in Delcath Systems in the fourth quarter worth about $34,000. Quantbot Technologies LP acquired a new position in shares of Delcath Systems during the fourth quarter valued at about $66,000. Point72 Asia Singapore Pte. Ltd. acquired a new stake in Delcath Systems in the 3rd quarter worth approximately $102,000. Barclays PLC acquired a new stake in Delcath Systems in the 3rd quarter worth approximately $104,000. Finally, Jane Street Group LLC purchased a new stake in Delcath Systems during the 3rd quarter worth approximately $110,000. 61.12% of the stock is currently owned by hedge funds and other institutional investors.

Delcath Systems Company Profile

Delcath Systems, Inc, an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company’s lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects.